Explore ViiV Healthcare

I am a
  • HCP
  • person living with HIV
  • NGO or patient group
  • job seeker
  • member of the public
  • academia / entrepreneur
  • media
...looking for
  • information about VHC medicines
  • clinical data and insights on VHC medicines
  • Independent Medical Education
  • medicines in development
  • how VHC is advancing HIV treatment and care
...looking for
  • information about VHC medicines
  • information and support about living with HIV
  • how to report a side effect
  • news and stories from ViiV Healthcare
...looking for
  • funding / grants
  • ViiV Healthcare's approach to partnerships
  • how ViiV Healthcare works with NGOs
  • news and stories from ViiV Healthcare
  • connect with ViiV Healthcare's community
...looking for
  • job opportunities
  • information about ViiV Healthcare
  • ViiV Healthcare's office locations
  • news and stories from ViiV Healthcare
...looking for
  • who are ViiV Healthcare
  • corporate ethics & compliance
  • news and stories from ViiV Healthcare
...looking for
  • opportunities to partner with ViiV Healthcare
  • information on ViiV Healthcare's Innovation Unit
  • news and stories from ViiV Healthcare
...looking for
  • press releases
  • ViiV Healthcare's Leadership
  • news and stories from ViiV Healthcare

Medical Education - ViiV HC CALL FOR PROPOSAL

Strategic priorities

  • Optimize HIV care beyond the viral control
    • Therapeutic objectives and new outcomes for long-term management of HIV infection: the role of PROMs and PREMs as new key outcomes
    • The role of “medication burden” and “deprescribing” in chronic HIV management
    • What are the guideline recommendations for selection of effective and friendly ARV regimen (durable efficacy and low long-term toxicities) in different HIV populations and which classes drive treatment choice
    • Why, When & How switch treatment in HIV virosuppressed pts
    • ARVs and disease metabolic impact, long term metabolic toxicities, weight gain in PLWH.
  • Role of core agents for best regimens across all appropriate patient types
    • What are the recommendations for selection of core agent in different regimens; specifically:
      • What is the impact of boosting
      • What is the significance of barrier to resistance of the regimen.
  • Managing patients with complex co-morbidities and/or those under represented in clinical trials
    • What are the guidelines for treatment of co-infected patients (HCV/HBV, TB) and what data are available
    • Considerations for management of women, adolescents, children, aging patients, late presenters and/or high viral load patients, HTE (Highly Treatment Experienced) pts
  • Evolving treatment paradigms
    • What is current research focusing on? Is there a role for changing approaches to ARV combinations (including 2DR, novel delivery methods, new MoA)
    • Very early treatment in new HIV diagnosis: same day treatment vs early personalised treatment
    • HIV treatment in a aging population: comorbidities, polipharmacy, deprescribing geriatric approach
    • How to treat MDR and HTE patients
  • Other strategic areas of interest for ViiV include:
    • Cascade of care
    • Remission
    • Cure
    • Prevention
    • Management of virologically failing patient
  • Other strategic areas of interest for ViiV Italy include:
    • Diagnostics and virology
    • Biology and Pharmacology of ARVs
    • Immunology in HIV
    • Health Outcome Research in HIV
    • Health Economics of HIV management
    • Methodology in Observational and clinical studies in HIV
    • Methodology of Health Technology Assessment for HIV treatment


10th February 2021